In fiscal 2025, which ended Jan 2, 2026, Exelixis, Inc. reported revenue of $2.3 billion, up 7.0% from the year before. Net income was $782.6 million, a profit margin of 33.7%. Operating income came to $872.2 million, an operating margin of 37.6%. Diluted earnings per share were $2.78. Over the twelve months ended Oct 2, 2026, revenue was $2.5 billion and net income was $885.1 million. Across the 10 fiscal years shown, revenue grew from $191.5 million in fiscal 2016 to $2.3 billion in fiscal 2025, about 31.9% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Oct 2, 2026
|
FY 2025
Jan 2, 2026
|
FY 2024
Jan 3, 2025
|
FY 2023
Dec 29, 2023
|
FY 2022
Dec 30, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Jan 1, 2021
|
FY 2019
Jan 3, 2020
|
FY 2018
Dec 28, 2018
|
FY 2017
Dec 29, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2,497
+9.1%
|
2,320
+7.0%
|
2,169
+18.5%
|
1,830
+13.6%
|
1,611
+12.3%
|
1,435
+45.3%
|
988
+2.0%
|
968
+13.3%
|
854
+88.7%
|
452
+136.3%
|
191
+415.0%
|
| Cost of revenue |
93
+20.9%
|
84
+9.8%
|
76
+5.1%
|
73
+25.3%
|
58
+9.5%
|
53
+45.8%
|
36
+9.6%
|
33
+25.6%
|
26
+74.9%
|
15
+129.9%
|
7
+68.2%
|
| Gross profit |
2,404
+8.7%
|
2,236
+6.9%
|
2,092
+19.0%
|
1,758
+13.2%
|
1,553
+12.4%
|
1,382
+45.3%
|
951
+1.8%
|
935
+13.0%
|
827
+89.2%
|
437
+136.6%
|
185
+455.6%
|
| Research and development |
835
-3.0%
|
825
-9.4%
|
910
-12.8%
|
1,044
+17.1%
|
892
+28.6%
|
694
+26.6%
|
548
+62.6%
|
337
+84.9%
|
182
+62.5%
|
112
+16.9%
|
96
-0.4%
|
| Selling, general and administrative |
565
+6.6%
|
519
+5.4%
|
492
-9.3%
|
543
+18.0%
|
460
+14.5%
|
402
+36.9%
|
293
+28.5%
|
228
+10.6%
|
206
+29.5%
|
159
+37.2%
|
116
+102.7%
|
| Restructuring and impairment |
1
-96.5%
|
21
-39.1%
|
34
|
—
|
—
|
—
|
—
|
—
|
0
+100.0%
|
-0
-103.5%
|
1
-12.3%
|
| Operating expenses |
1,400
-0.8%
|
1,364
|
—
|
1,587
+17.4%
|
1,352
+23.4%
|
1,095
+30.2%
|
841
+48.8%
|
565
+45.4%
|
389
+43.1%
|
272
+27.4%
|
213
+37.7%
|
| Operating income |
1,003
+25.4%
|
872
+44.3%
|
605
+253.8%
|
171
-15.2%
|
201
-29.7%
|
287
+160.5%
|
110
-70.2%
|
369
-15.8%
|
439
+164.5%
|
166
+689.9%
|
-28
+76.8%
|
| Pretax income |
—
|
—
|
—
|
—
|
—
|
—
|
131
-67.1%
|
398
-11.9%
|
452
+185.1%
|
159
+325.8%
|
-70
+56.6%
|
| Income tax |
181
-7.5%
|
159
-1.1%
|
160
+222.3%
|
50
-4.4%
|
52
-17.5%
|
63
+231.1%
|
19
-75.3%
|
77
+132.4%
|
-238
-5570.8%
|
4
|
0
-100.0%
|
| Net income |
885
+30.6%
|
783
+50.1%
|
521
+150.9%
|
208
+14.0%
|
182
-21.1%
|
231
+106.7%
|
112
-65.2%
|
321
-53.5%
|
690
+347.4%
|
154
+319.6%
|
-70
+56.6%
|
| Basic EPS |
3.46
+41.2%
|
2.88
+60.0%
|
1.80
+176.9%
|
0.65
+14.0%
|
0.57
-21.9%
|
0.73
+102.8%
|
0.36
-66.0%
|
1.06
-54.3%
|
2.32
+346.2%
|
0.52
|
—
|
| Diluted EPS |
3.34
+41.2%
|
2.78
+58.0%
|
1.76
+170.8%
|
0.65
+16.1%
|
0.56
-22.2%
|
0.72
+105.7%
|
0.35
-65.7%
|
1.02
-53.8%
|
2.21
+351.0%
|
0.49
|
—
|
| Weighted average shares, basic |
256
-7.5%
|
272
-6.4%
|
290
-8.8%
|
318
-1.0%
|
322
+2.1%
|
315
+2.1%
|
308
+1.9%
|
303
+1.6%
|
298
+1.5%
|
294
|
—
|
| Weighted average shares, diluted |
265
-7.5%
|
282
-4.8%
|
296
-7.9%
|
321
-1.0%
|
325
+0.7%
|
322
+1.4%
|
318
+0.9%
|
315
+0.7%
|
313
+0.3%
|
312
|
—
|
| Other measures | |||||||||||
| Depreciation and amortization |
28
-6.5%
|
29
+0.9%
|
29
+12.0%
|
26
+23.2%
|
21
+53.2%
|
14
+49.1%
|
9
+9.5%
|
8
+69.8%
|
5
+314.1%
|
1
+18.5%
|
1
-28.7%
|
| EBITDA |
1,031
+24.3%
|
901
+42.3%
|
633
+222.2%
|
197
-11.6%
|
222
-26.0%
|
300
+151.9%
|
119
-68.5%
|
378
-14.9%
|
444
+165.6%
|
167
+716.1%
|
-27
+77.4%
|
| Interest coverage |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
19.12x
|
-0.85x
|
| Margins | |||||||||||
| Gross margin |
96.26%
|
96.39%
|
96.49%
|
96.04%
|
96.41%
|
96.32%
|
96.33%
|
96.58%
|
96.91%
|
96.67%
|
96.58%
|
| Operating margin |
40.19%
|
37.59%
|
27.88%
|
9.34%
|
12.51%
|
19.98%
|
11.14%
|
38.18%
|
51.40%
|
36.67%
|
-14.69%
|
| Pretax margin |
—
|
—
|
—
|
—
|
—
|
—
|
13.25%
|
41.14%
|
52.95%
|
35.05%
|
-36.68%
|
| Profit margin |
35.45%
|
33.73%
|
24.04%
|
11.35%
|
11.31%
|
16.10%
|
11.32%
|
33.17%
|
80.82%
|
34.09%
|
-36.68%
|
| EBITDA margin |
41.30%
|
38.84%
|
29.21%
|
10.74%
|
13.80%
|
20.93%
|
12.07%
|
39.04%
|
51.97%
|
36.93%
|
-14.17%
|
| Effective tax rate |
—
|
—
|
—
|
—
|
—
|
—
|
14.56%
|
19.37%
|
-52.64%
|
2.74%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXEL (Nasdaq)
- Fiscal year ends
- January 1
- Incorporated in
- DE
- Headquarters
- Alameda, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 939767
- Former names
- EXELIXIS INC (until Sep 12, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.